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Abstract
Objective To prospectively compare the renal safety of
meglumine gadoterate (Gd-DOTA)-enhanced magnetic res-
onance imaging (MRI) to a control group (unenhanced
MRI) in high-risk patients.
Methods Patients with chronic kidney disease (CKD)
scheduled for MRI procedures were screened. The primary
endpoint was the percentage of patients with an elevation of
serum creatinine levels, measured 72±24 h after the MRI
procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from
baseline. A non-inferiority margin of the between-group
difference was set at −15 % for statistical analysis of the
primary endpoint. Main secondary endpoints were the var-
iation in serum creatinine and eGFR values between base-
line and 72±24 h after MRI and the percentage of patients
with a decrease in eGFR of at least 25 % from baseline.
Patients were screened for signs of nephrogenic systemic
fibrosis (NSF) at 3-month follow-up.
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Results Among the 114 evaluable patients, one (1.4 %) in
the Gd-DOTA-MRI group and none in the control group
met the criteria of the primary endpoint [Δ0−1.4 %, 95%CI 0
(−7.9 %; 6.7 %)]. Non-inferiority was therefore demonstrated
(P00.001). No clinically significant differences were ob-
served between groups for the secondary endpoints. No
serious safety events (including NSF) were noted.
Conclusion Meglumine gadoterate did not affect renal func-
tion and was a safe contrast agent in patients with CKD.
Key points
• Contrast-induced nephropathy (CIN) is a potential
problem following gadolinium administration for MRI.
• Meglumine gadoterate (Gd-DOTA) appears safe, even
in patients with chronic kidney disease.
• Gd-DOTA only caused a temporary creatinine level
increase in 1/70 such patients.
• No case or sign of NSFwas detected at 3-month follow-up.
Keywords Gadolinium-based contrast agent-induced
nephropathy . Gd-DOTA .Meglumine gadoterate . MRI .
Nephrogenic systemic fibrosis
[3–5]. These discrepancies could be due to multiple factors:
different doses and routes of administration of GBCAs, het-
erogeneous study designs and CIN definitions with the use of
different formulas to estimate the glomerular filtration rate
(eGFR), non-systematic use of prophylactic measures, and
possible differences between GBCAs in terms of their intrinsic
nephrotoxic potential [4]. CIN has never been described after
administration of meglumine gadoterate (Gd-DOTA) alone, a
molecule in which gadolinium is chelated (“caged”) by a
macrocyclic ligand. The absence of CIN after Gd-DOTA
administration was initially demonstrated in a small, rando-
mised study conducted in CKD patients [6]. The absence of
impact of Gd-DOTA on renal function was further docu-
mented in a large Japanese post-marketing study [7], and its
good overall safety was confirmed in a surveillance study of
84,621 patients, including 764 patients with renal failure [8].
In a retrospective study conducted by Ergün et al [9] in 91
patients with stage 3 and 4 CKD [mean eGFR by the modified
MDRD formula (Modification of Diet in Renal Disease):
33 ml/min/1.73 m2] assessed by magnetic resonance imaging
(MRI) with an intravenous dose of 0.2 mmol/kg of Gd-DOTA,
gadopentetate dimeglumine, or gadodiamide, 11 patients
(12.1 %) developed CIN. However, the respective CIN rate
for each GBCA was not specified, and differences in renal
toxicity between these GBCAs therefore cannot be excluded.
The primary objective of this prospective study was to assess
the CIN rate in a similar population of patients with stable
stage 3 and 4 CKD undergoing Gd-DOTA-enhanced MRI
compared with a control group undergoing unenhanced MRI.
Subjects and methods
Study design
This phase IV (RESCUE trial), open-label, non-randomised,
multinational study compared the renal safety of Gd-DOTA-
enhancedMRIwith unenhancedMRI in high-risk patients. The
study was registered at ClinicalTrials.gov, no. NCT00650845.
Institutional Review Board and regulatory approval was
granted for each centre and all patients gave their written
informed consent.
Patients
Patients (male or female, aged ≥18 years) with known stable
stage 3 or 4 CKD according to the Kidney Disease Improving
Global Outcomes (KDIGO) definition (i.e. eGFR >15ml/min/
1.73 m2 and <60 ml/min/1.73 m2) scheduled to undergo MRI
were included.
Patients were ineligible when surgery or chemotherapy
was planned within 72 h post-procedure; if they had under-
gone an imaging procedure (MRI or computed tomography
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Introduction
Contrast-induced nephropathy (CIN), part of a broader spec-
trum of acute kidney injuries [1], was first reported after
administration of iodinated contrast media (CM) [2]. The
European Society of Urogenital Radiology (ESUR) guidelines
define CIN as acute kidney injury within days following CM
administration when alternative causes of renal damage have
been excluded [1]. The development of CIN after administra-
tion of gadolinium-based contrast agents (GBCAs) remains
controversial, especially in high-risk groups such as patients
with chronic kidney disease (CKD), in whom CIN has been
inconsistently reported after injection of various GBCAs
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with or without contrast medium) during the 7 days before
inclusion, or within 72 h post-procedure; if they had partic-
ipated in any investigational drug study during the 30 days
prior to inclusion or were scheduled to participate in
another study within 72 h post-procedure; or had a known
allergy to GBCAs.
Patients with a contraindication to MRI, a diagnosis of
haemodynamic instability or acute myocardial infarction
during the 2 weeks prior to inclusion, requiring haemodial-
ysis, with newly diagnosed unstable diabetes, or pregnant
women were ineligible. All patients who had received any
medication known to be nephrotoxic or cause elevation of
serum creatinine levels during the 2 weeks before the base-
line blood sample and throughout the study duration were
not included in the study (a list of nephrotoxic medications
was established at the beginning of the trial and given to
each site). Moreover, at the end of the study, all patient
medications were reviewed by an independent expert
(nephrologist) blinded to the imaging procedure performed.
Any included patient having received nephrotoxic treatment
was identified and considered as a protocol deviation.
A patient was considered to be screened but not yet
included until the first blood sample had been drawn within
1 day before MRI (baseline). A patient was definitively
included in the absence of any exclusion criteria and when
(1) the relative difference between baseline serum creatinine
and a previous serum creatinine value, obtained at least
1 week and less than 6 months before the baseline blood
test, did not exceed 15 % and (2) the eGFR value according
to the abridged MDRD study prediction equation [10] was
>15 ml/min/1.73 m2 and <60 ml/min/1.73 m2.
MRI procedure and Gd-DOTA administration
According to the investigator’s judgement (i.e. diagnosis
needed) and the hospital’s standard practices, patients were
assigned to the Gd-DOTA-enhanced MRI group or the
unenhanced MRI group. In each centre, MRI procedures
were performed according to the hospital’s standard proto-
cols. Gd-DOTA (Dotarem®, Guerbet, Roissy CdG, France)
was to be injected intravenously by a power injector at a
dose of 0.1 mmol/kg (0.2 ml/kg).
Safety assessment
Serum creatinine and other laboratory parameters (sodium,
potassium, bicarbonate, calcium, uric acid, haematocrit, and
haemoglobin) were assayed in the same laboratory for each
patient for both pre- and post-MRI blood samples.
The primary endpoint was nephrotoxicity, defined as the
percentage of patients with serum creatinine level elevation,
determined 72±24 h after MRI, of at least 25 % or
44.2 μmol/l (0.5 mg/dl) above the baseline value.
Secondary endpoints were: variation in (1) serum creat-
inine and (2) eGFR values between baseline and 72±24 h
after MRI as well as the percentage of patients with a
decrease in eGFR of at least 25 % from baseline values,
the percentage of patients who met the criteria of the prima-
ry endpoint and for whom serum creatinine returned to the
baseline value 14 days after MRI, and the potential influ-
ence on renal function of the measures to prevent CIN
(medication/hydration). There was no specific hydration
protocol defined in this study and the sites followed their
routine practice. Nonetheless, whenever possible, the patient
was encouraged to drink liberally before and after the injec-
tion. Special attention was paid to acute and delayed allergy-
like reactions. The number of dialysis sessions after MRI
was also recorded.
Patients were monitored for adverse events from the time
informed consent was signed until 72±24 h after MRI. In
case of CIN, renal function was to be checked via a third
blood sample 14 days after the imaging procedure in the
same laboratory as the two others. The patient was then
followed up until complete resolution of the CIN.
Adverse events reported by the local investigators were
classified as serious or non-serious and assessed according
to their clinical severity (mild, moderate, or severe) and their
relationship (possible, doubtful, or not related) to the study
contrast agent or the unenhanced-MRI procedure. Outcomes
of adverse events were classified into the following catego-
ries: resolved with or without sequelae, ongoing, worsened
at the time of the report, or death.
Vital signs (blood pressure, pulse) were monitored
just before each MRI procedure, then 15 min and 1 h
after the procedure.
Each patient was contacted 3 months after the MRI exam
to detect any symptoms or signs suggestive of nephrogenic
systemic fibrosis (NSF). This 3-month follow-up was cho-
sen according to the average time of NSF onset as suggested
by several publications [11–14].
Statistical analysis
All statistical analyses were performed with SAS version
9.2 software (SAS Institute Inc, Cary, NC) at the P<0.05
level of significance.
Based on data published by Ergün et al. [9], we assumed
an average incidence of 12 % CIN in each group. A total of
120 evaluable patients was considered to be a sufficient
sample size to ensure, with 80 % power and at a 5 % one-
sided significance level, that non-inferiority of Gd-DOTA-
MRI over unenhanced MRI could be demonstrated with a
fixed −15 % non-inferiority margin. In other words, non-
inferiority would be demonstrated if the lower bound of the
95 % confidence interval (CI) of the difference of percent-
age of patients who met the criteria of the primary endpoint
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(unenhanced-MRI patients – Gd-DOTA MRI patients) was
greater than −15 %. Assuming a 10 % dropout rate during
the study, a total of 134 patients were deemed necessary to
achieve the study objectives. The secondary endpoints
(variation from baseline of serum creatinine concentra-
tion and eGFR level, or decrease in eGFR level from
baseline ≥25 %) were investigated by regression models
with adjustment for centres.
Student’s t test and Fisher’s exact test were used for the
other parameters.
Two data analysis populations were defined from all
patients screened in the study.
The Evaluable Safety Population (ESP) included all
patients for whom two blood samples were available for
pre- and post-MRI serum creatinine assay. This population
was used for analysis of the primary endpoint and all other
safety analyses (including adverse events, laboratory data,
and vital signs).
The per-protocol (PP) population was a subpopulation of
ESP, i.e. evaluable patients not presenting any significant
protocol deviations or violations. This population was used
for analysis of the primary endpoint as well as serum creat-
inine and eGFR level variations from baseline.
Propensity score analysis was planned to balance the
absence of randomisation to assign patients to unenhanced
or Gd-DOTA-enhanced MRI except when baseline statisti-
cal tests demonstrated that the two groups were homoge-
neous at inclusion.
Results
Patients eligible for analysis
A total of 142 patients were screened in 15 centres in Europe
(Belgium, France, Italy, and Spain), 135 were included, and
114 were evaluable for the primary endpoint (70 in the Gd-
DOTA MRI group and 44 in the unenhanced-MRI group).
Patient disposition is described in the study patient flow
chart (Fig. 1).
As shown in Table 1, the two groups of the ESP were
well balanced in terms of demographic and baseline data.
No significant difference was observed between the two
groups for sex ratio (P00.529), age (P00.428), body mass
index (P00.790), baseline serum creatinine (P00.367) lev-
el, or baseline eGFR level (P00.641).
A history of known allergic reactions was reported in 12
patients (17.1 %) in the Gd-DOTA-MRI group and 7
patients (15.9 %) in the unenhanced-MRI group.
The various types of MRI procedures are shown in
Table 2. The most common procedures were body MRI
(43.9 %) and MR angiography (21.9 %). No significant
between-group differences were observed.
Gd-DOTA was administered intravenously at a mean
dose of 0.1 mmol/kg (range: 0.06–0.29 mmol/kg) and at a
mean flow rate of 2 ml/s (range: 0.7–4 ml/s).
Primary endpoint: serum creatinine level increase
from baseline ≥25 % or ≥44.2 μmol/l (0.5 mg/dl)
As shown in Table 3, in the ESP, one patient (1.4 %) in the
Gd-DOTA-MRI group and no patients in the control group
met the criteria of the primary endpoint with a mean differ-
ence (unenhanced-MRI – Gd-DOTA-MRI) of −1.4 % [95 %
CI 0 (−7.9 %; 6.7 %)]. As the lower bound of the 95 % CI
(−7.9 %) was superior to the non-inferiority margin
(−15 %), the non-inferiority of Gd-DOTA-MRI over unen-
hanced MRI was demonstrated (P00.001). Consistent
results were observed in the PP population (67 patients),
with a mean difference of −2.7 % [95%CI 0 (−14.1 %;
8.9 %), P00.0204].
In the patient who met the criteria of the primary end-
point (male subject, age: 68 years with type 2 diabetes
mellitus, body mass index: 33.4 kg/m2; Gd-DOTA dose:
0.095 mmol/kg), the baseline serum creatinine level
(176.8 μmol/l (2 mg/dl)) rose to 229.8 μmol/l (2.6 mg/dl)
after MRI, i.e. a relative increase of 30 % and an absolute
increase of 53 μmol/l (0.6 mg/dl), and returned to baseline
within 2 weeks.
Secondary endpoints
As shown in Table 4, no significant difference in serum
creatinine level variation from baseline was observed in
the ESP (−1.40 % in the Gd-DOTA group vs. –3.48 % in
the unenhanced group). This was confirmed in the PP pop-
ulation (0.05 % in the Gd-DOTA group vs. –5.17 % in the
unenhanced group).
The same trend is observed for the eGFR level variation
from baseline in the ESP (3.02 % in the Gd-DOTA group vs.
5.55 % in the unenhanced group) and PP (1.37 % in the Gd-
DOTA group vs. 7.58 % in the unenhanced group). A 26 %
decrease in the eGFR value was observed in the single
patient with CIN (baseline eGFR: 35.4 ml/min/1.73 m2
and post-MRI eGFR: 26.2 ml/min/1.73 m2).
As shown in Table 1, the rate of use of patient hydration
or other prophylactic measures was very low in the two
groups (2 patients in the Gd-DOTA-MRI group and no
patients in the unenhanced-MRI group).
In both groups, no patients developed acute and delayed
allergy-like reactions, and no patients required dialysis
after MRI.
No adverse events were observed in the unenhanced-
MRI group. Five adverse events were observed in five
patients (7.1 %) after Gd-DOTA-enhanced MRI (abdominal
pain, haematoma, constipation, toothache, and increase of
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blood creatinine levels). One adverse event (hypotension)
occurred before Gd-DOTA injection. No statistically signif-
icant between-group difference was observed (P00.080).
All adverse events were non-serious, mild, resolved within
3 weeks, and were not related to Gd-DOTA injection (ex-
cept for elevation of serum creatinine levels in the single
patient with CIN, which was possibly related to Gd-DOTA).
Vital sign variations from baseline (Table 5) were com-
parable between groups (except for systolic blood pressure
at the 1-h time point), and no clinically significant out-of-
range variation was observed. Variations from baseline in
haematological and biochemistry parameters were compa-
rable between groups (Table 5). All values out of the normal
range were classified as not clinically significant.
No signs suggestive of NSF were observed at 3-month
follow-up.
As baseline statistical tests showed that the two groups
were well balanced in terms of demographic and baseline
data, the results of the propensity score analysis did not
provide any additional value.
Discussion
This prospective study showed a very similar low rate of
CIN after Gd-DOTA-enhanced MRI (1.4 %) and unen-
hanced MRI (0 %) in patients with stage 3 or 4 CKD. Apart
from two small trials conducted with GBCAs versus a
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Fig. 1 Study patient flow chart
control group [6, 15], RESCUE is the only large-scale pro-
spective study in CKD patients comparing GBCA-enhanced
MRI to unenhanced MRI. This is an important point, as the
serum creatinine level has been reported to increase in patients
not receiving contrast material just as frequently as in series of
patients who received contrast material [16].
The primary endpoint strictly complied with the current
ESUR guidelines [1]. Despite similar patient characteristics,
the same intravenous route of administration and a less strin-
gent definition of CIN than that reported by Ergün et al.—
elevation of serum creatinine levels by at least 44.2 μmol/
l (0.5 mg/dl) over baseline values within 24–72 h after CM
administration [9]—our 1.4 % CIN rate was lower than the
12.1 % rate reported in the previously published retrospective
study, which was used to define the −15 % non-inferiority
margin. The higher dose of GBCA used by Ergün et al.
(0.2 mmol/kg) might be an explanation. Although the −15 %
margin is now questionable in view of the low CIN rate
observed in our prospective study, it is to be noted that,
according to protocol hypothesis, the 120 subjects of RES-
CUE would have allowed demonstrating non-inferiority with
a margin set as low as -4.5 %, so these results show that
patients undergoing Gd-DOTA-enhanced MRI did not have
any clinically significant increased risk of CIN.





bMean BMI calculated on 68






Age (years) 69.1±11.5 67.3±12.0 68.4±11.7 P00.428
Mean ± SD (min/max) (34/92) (26/86) (26/92)
Gender n (%) P00.529
Male 47 (67.1 %) 27 (61.4 %) 74 (64.9 %)
Female 23 (32.9 %) 17 (38.6 %) 40 (35.1 %)
BMI (kg/m2) 27.5±4.9b 27.3±3.9 27.4±4.6 P00.790
Mean ± SD (min/max) (16.0/41.2) (18.8/36.4) (16.0/41.2)
Serum creatinine (μmol/l) 175.9±65.4 165.3±59.2 171.5±62.8 P00.367
Mean ± SD (min/max) (79.6/371.3) (88.4/344.8) (79.6/371.3)
eGFR (ml/min/1.73 m2) 37.58±13.6 38.78±12.6 38.04±13.2 P00.641
Mean ± SD (min/max) (15.0/82.0) (17.0/65.3) (15.0/82.0)
History of allergy, n (%) 12 (17.1 %) 7 (15.9 %) 19 (16.7 %) P01.000
Premedication/prehydration, n (%) 2 (2.9 %) 0 (0.0 %) 2 (1.8 %) P00.517




aA patient with multiple indica-
tions is counted several times









Body (abdomen/thorax) 37 (52.9 %) 13 (29.5 %) 50 (43.9 %)
Kidney 23 (32.9 %) 10 (22.7 %) 33 (28.9 %) P00.134
Pelvis 8 (11.4 %) 1 (2.3 %) 9 (7.9 %)
Limbs 4 (5.7 %) 0 (0.0 %) 4 (3.5 %)
Liver 0 (0.0 %) 2 (4.5 %) 2 (1.8 %)
Pancreas 1 (1.4 %) 0 (0.0 %) 1 (0.9 %)
Heart 1 (1.4 %) 0 (0.0 %) 1 (0.9 %)
Angiography 20 (28.6 %) 5 (11.4 %) 25 (21.9 %)
Renal 15 (21.4 %) 4 (9.1 %) 19 (16.7 %) P00.781
Carotid 1 (1.4 %) 1 (2.3 %) 2 (1.8 %)
Aorto-iliac 2 (2.9 %) 0 (0.0 %) 2 (1.8 %)
Other 2 (2.9 %) 0 (0.0 %) 2 (1.8 %)
Musculoskeletal system
(bones/joints)
2 (2.9 %) 14 (31.8 %) 16 (14.0 %) –
Central nervous system 1 (1.4 %) 9 (20.5 %) 10 (8.8 %)
Brain 1 (1.4 %) 7 (15.9 %) 8 (7.0 %) P01.000
Head/neck 0 (0.0 %) 2 (4.5 %) 2 (1.8 %)
Other indications 10 (14.3 %) 6 (13.6 %) 16 (14.0 %) –
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In the other four studies [17–20] in which GBCA-related
nephrotoxicity was reported in CKD patients, two studies [17,
18] also reported a higher CIN rate (50 % and 28 %, respec-
tively). Compared to RESCUE, CIN occurred in populations
with similar degrees of CKD, but with globally smaller num-
ber of patients (10 [17] and 25 [18]), definitions of CIN that
did not strictly comply with ESUR guidelines—more than
50 % decrease in GFR [17], at least 44.2 μmol/l (0.5 mg/dl)
increase of baseline serum creatinine levels at 48 h, or need for
dialysis within 5 days [18]—and high doses of CM: 0.57±
0.17 mmol/kg [17] or 0.6±0.3 mmol/kg [18] for angiographic
examinations. The common denominator of the three studies
[9, 17, 18] was the use of GBCAs with different structures:
gadopentetate dimeglumine [9], gadodiamide [9, 18], gado-
butrol [17, 18], and Gd-DOTA [9]. This could at least partly
explain the higher CIN rates compared to that observed with
Gd-DOTA alone, although a number of published studies
have also shown that administration of these GBCAs is asso-
ciated with no or a low rate of CIN in CKD patients [3–5] and
have even reported a serum creatinine level decrease after the
administration of gadolinium [21]. In the remaining two stud-
ies [19, 20], conducted with some of these GBCAs, lower CIN
rates were observed: 1.9 % [19] and 2.5 % [20]. The differ-
ences with RESCUE, despite higher doses of GBCAs, were
either a more stringent definition of CIN (at least 1.0 mg/dl
increase in baseline serum creatinine levels at 48 h and oli-
goanuria [19]) in a similar CKD population (mean baseline
creatinine clearance: 38.2±16 ml/min) [19] or a less severe
CKD population (46.8 % of patients with mild CKD) with a
different CIN definition (greater than 25 % decrease of base-
line GFR) [20].
The mechanism of the putative nephrotoxicity of
GBCAs is unknown (related to the different GBCA struc-
tures or free gadolinium) [3, 4]. High doses of GBCAs
have been recognised as a risk factor in CKD patients [1],
but even approved doses have been shown to be associ-
ated with occasional cases of CIN [22]. Acute tubular
necrosis lesions, following sequential administration of
two GBCAs, have been described in the only case documented
by kidney biopsy [23].
Table 3 Primary endpoint: number (%) of patients with serum creatinine level variation from baseline ≥25 % or ≥44.2 μmol/l (0.5 mg/dl) in the
evaluable safety population and per-protocol population
Gd-DOTA-MRI Unenhanced MRI Test
Evaluable safety population (n070) (n044) Difference (unenhanced-MRI – Gd-DOTA-MRI) 0 −1.4 %
1 (1.4 %) 0 (0.0 %) Exact 95 %CI 0 [−7.9 %; 6.7 %]
P00.001a
Per-protocol population (n037) (n030) Difference (unenhanced-MRI – Gd-DOTA-MRI) 0 −2.7 %
1 (2.7 %) 0 (0.0 %) Exact 95 %CI 0 [−14.1 %; 8.9 %]
P00.0204b
a P-value testing the difference −1.4 % vs. −15 % (non-central Student’s t-test)
b P-value testing the difference −2.7 % vs. −15 % (non-central Student’s t-test)
Table 4 Serum creatinine and eGFR level variations from baseline, evaluable safety population and per-protocol population
Secondary endpoints Gd-DOTA-MRI Unenhanced MRI Student’s t-test
Serum creatinine level variation from baseline (%) (mean ± SD, min/max)
Evaluable safety population (n070) (n044) Difference (Gd-DOTA-MRI - unenhanced-MRI) 0 2.08 %
−1.40±10.36 −3.48±9.92 95 %CI 0 [−1.80 %; 5.97 %]
(−25.00/30.00) (−28.57/18.05) P00.291
Per-protocol population (n037) (n030) Difference (Gd-DOTA-MRI - unenhanced MRI) 0 5.21 %
0.05±10.84 −5.17±9.16 95 %CI 0 [0.24 %; 10.18 %]
(−21.02/30.00) (−28.57/14.46) P00.040
eGFR level variation from baseline (%) (mean ± SD, min/max)
Evaluable safety population (n070) (n044) Difference (Gd-DOTA-MRI - unenhanced-MRI) 0 −2.53 %
3.02±12.51 5.55±12.94 95 %CI 0 [−7.37 %; 2.30 %]
(−26.12/39.37) (−17.42/47.45) P00.301
Per-protocol population (n037) (n030) Difference (Gd-DOTA-MRI - unenhanced-MRI) 0 −6.22 %
1.37±12.65 7.58±12.82 95 %CI 0 [−12.46 %; 0.03 %]
(−26.12/31.30) (−14.43/47.45) P00.051
1256 Eur Radiol (2013) 23:1250–1259
Another possible explanation for the low CIN rate ob-
served in our study would be biases induced by methodo-
logical issues. The heterogeneous indications for MRI did
not allow randomisation of procedures (Gd-DOTA-en-
hanced MRI versus unenhanced MRI) or a double-blind
design, as the investigators determined the type of procedure
according to the patient’s condition and underlying diseases.
However, despite the open-label design and absence of
randomisation, the baseline demographic characteristics, es-
pecially mean serum creatinine and mean eGFR levels, were
comparable between the two groups. The greater number of
patients in the Gd-DOTA group excluded from the PP
population did not affect the results of the primary endpoint
in the PP analysis compared to the ESP analysis.




Vital signs Gd-DOTA-MRI (n070) Unenhanced MRI (n044) Student’s t-test
Diastolic blood pressure (mmHg) (mean ± SD, min/max)
15 min (n064) (n041) P00.427
2.84±10.73 1.15±10.48
(−20/31) (−21/35)
1 h (n060) (n040) P00.173
0.62±11.58 −2.25±7.76
(−20/42) (−19/19)
Systolic blood pressure (mmHg) (mean ± SD, min/max)
15 min (n064) (n041) P00.067
4.84±16.52 −1.29±16.58
(−30/50) (−39/40)
1 h (n060) (n040) P00.044
1.62±17.86 −5.70±17.14
(−36/60) (−47/35)
Heart rate (bpm) (mean ± SD, min/max)
15 min (n063) (n040) P00.501
0.62±12.15 2.00±5.47
(−56/34) (−11/12)
1 h (n059) (n040) P00.568
0.90±9.66 1.95±7.80
(−22/35) (−15/16)
Laboratory data Gd-DOTA-MRI (n070) Unenhanced MRI (n044) Student’s t-test
Laboratory data – relative variations from baseline values (mean ± SD, min/max)
Bicarbonate (n065) (n030) P00.423
−0.01±0.09 0.01±0.11
(−0.22/0.23) (−0.23/0.35)
Calcium (n064) (n040) P00.825
−0.01±0.04 −0.00±0.04
(−0.13/0.15) (−0.14/0.09)
Haematocrit (n067) (n040) P00.364
−0.02±0.05 −0.01±0.07
(−0.17/0.12) (−0.17/0.24)
Haemoglobin (n067) (n041) P00.345
−0.02±0.04 −0.01±0.07
(−0.16/0.10) (−0.16/0.30)
Potassium (n069) (n043) P00.426
−0.01±0.08 −0.02±0.09
(−0.20/0.23) (−0.24/0.19)
Sodium (n070) (n043) P00.646
0.00±0.02 −0.00±0.01
(−0.04/0.04) (−0.05/0.02)
Uric acid (n061) (n041) P00.197
−0.01±0.08 −0.03±0.11
(−0.16/0.17) (−0.29/0.26)
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Finally, measures to prevent CIN would not provide an
explanation, as they were rarely used.
The results of this study confirm the absence of impact of
Gd-DOTA on renal function, as already observed when
administered to a small cohort of ten patients with CKD
undergoing MRI compared to ten patients not receiving CM
[6]. The mean (standard error of the mean) serum creatinine
values (μmol/l) at baseline and 48 h post-procedure were
330.9 (42.2) and 306.2 (44.7), respectively, in the Gd-
DOTA group and 329.7 (53.9) and 344.6 (64.9), respective-
ly, in the control group. This absence of impact on renal
function was also recently documented in a post-marketing
study conducted in 3,444 Japanese patients [7]. Kidney
function tests, performed as part of routine medical care in
patients with impaired renal function, did not reveal any
significant difference in terms of serum creatinine values
(μmol/l; mean ± standard deviation) before (194.5±194.5)
and after (203.3±194.5) Gd-DOTA administration.
Nephrogenic systemic fibrosis is a rare but occasion-
ally life-threatening complication of GBCA exposure that
occurs in patients with severe CKD [4, 24]. No uncon-
founded case of NSF has so far been reported with Gd-
DOTA administration, and no signs of this condition
were detected at 3-month follow-up in the present study.
This is in accordance with a statement recently issued by
the European Medicines Agency [25] where macrocyclic
chelates including Gd-DOTA were considered to be low-
risk for NSF.
In conclusion, no clinically relevant differences in
terms of the risk of nephrotoxicity (CIN) and general
safety profile were observed in a population of high-
risk patients with stable stage 3 and 4 CKD undergoing
MRI after intravenous injection of Gd-DOTA compared
to those not receiving Gd-DOTA.
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